Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy

- Innovation Passport award facilitates accelerated time to market and helps expedite patient access to transformative new medicines - 

- New Innovative Licensing and Access Pathway (ILAP) designation provides unique, end-to-end regulatory access pathway for Solid to work directly with the UK’s National Health System (NHS), the UK Medicines and Healthcare products Regulatory Agency (MHRA) and health technology assessment (HTA) bodies: the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and the All Wales Therapeutics and Toxicology Centre (AWTTC) -

Read more at globenewswire.com